Austin, TX 的 偏頭痛 臨床試驗
8 項針對 偏頭痛 的研究正在 Austin（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Study of EVO756 in Adults With Migraine
招募中2 期
- FutureSearch Trials of Neurology, Austin
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
招募中3 期
- Dell Children's Medical Center, Austin
- Child Neurology Consultants of Austin - Central Austin, Austin
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
招募中3 期
- Dell Children's Medical Center, Austin
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
招募中3 期
- UT Health Austin at Dell Childrens Neurology Clinic /ID# 270577, Austin
Responding With Evidence and Access for Childhood Headaches
招募中
- Dell Children's Hospital-UT Health, Austin
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
招募中3 期
- UT Health Austin at Dell Children's Neurology Clinic /ID# 244266, Austin
- Austin Regional Clinic - ARC Four Points /ID# 276301, Austin
- Velocity Clinical Research, Austin /ID# 230557, Austin
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
招募中3 期
- FutureSearch Trials of Neurology, Austin
- Tekton Research, Austin
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
招募中2 期
- FutureSearch Trials, Austin
其他城市的 偏頭痛 試驗
- Cincinnati, OH11 項研究
- Miami, FL8 項研究
- Philadelphia, PA8 項研究
- Concord, CA8 項研究
- Amherst, NY7 項研究
- Omaha, NE7 項研究
- Houston, TX7 項研究
- Washington, DC7 項研究
- Aurora, CO6 項研究
- Stamford, CT6 項研究
- San Diego, CA6 項研究
- Tampa, FL6 項研究
Austin 的其他研究
- 非小細胞肺癌30 項研究
- 癌症（所有類型）20 項研究
- 肥胖症20 項研究
- 轉移性癌症19 項研究
- 大腸直腸癌19 項研究
- 心臟衰竭18 項研究
- 乳癌18 項研究
- 過重18 項研究
- 卵巢癌17 項研究
- 子宮內膜癌15 項研究
- 前列腺癌15 項研究
- 憂鬱症14 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。